Pharsight

1. List of Androgel drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8741881	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8729057	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8754070	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8466136	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8759329	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8486925	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8466138	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)
US8466137	ABBVIE	Testosterone gel and method of use	Oct, 2026 (3 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 29 April, 2011

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

Strength	Dosage	Availability
1.62% (20.25MG/1.25GM ACTUATION)	GEL, METERED;TRANSDERMAL	Prescription
1.62% (20.25MG/1.25GM PACKET)	GEL;TRANSDERMAL	Discontinued
1.62% (40.5MG/2.5GM PACKET)	GEL;TRANSDERMAL	Discontinued

2. List of Tricor drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320802	ABBVIE	Methods of treatment using nanoparticulate fenofibrate compositions	Feb, 2023 (24 days from now)
US7276249	ABBVIE	Nanoparticulate fibrate formulations	Feb, 2023 (24 days from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 05 November, 2004

Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v)

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
48 mg	01 Jul, 2008	1	05 Apr, 2012	21 Feb, 2023	Extinguished
145 mg	19 Oct, 2007	1		21 Feb, 2023	Extinguished

Strength	Dosage	Availability
48MG	TABLET;ORAL	Prescription
145MG	TABLET;ORAL	Prescription

3. List of Trilipix drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7259186	ABBVIE	Salts of fenofibric acid and pharmaceutical formulations thereof	Jan, 2025 (1 year, 11 months from now)